Published in Mol Cancer Ther on July 17, 2012
Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors. J Immunol (2013) 0.87
Metastatic colon cancer cell populations contain more cancer stem-like cells with a higher susceptibility to natural killer cell-mediated lysis compared with primary colon cancer cells. Oncol Lett (2015) 0.83
Emerging roles for the FCRL family members in lymphocyte biology and disease. Curr Top Microbiol Immunol (2014) 0.81
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. Biomed Res Int (2015) 0.81
The development of potential antibody-based therapies for myeloma. Blood Rev (2014) 0.81
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing. Cancer Cell (2017) 0.77
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies. Biochim Biophys Acta (2016) 0.76
Fc Receptor-Like Proteins in Pathophysiology of B-cell Disorder. J Clin Cell Immunol (2016) 0.75
A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers. Oncotarget (2016) 0.75
Cryopyrin activates the inflammasome in response to toxins and ATP. Nature (2006) 18.74
A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16
Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med (2008) 5.48
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol (2005) 4.27
Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways. Cell (2011) 3.95
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 3.87
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A (2009) 3.13
Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis (2003) 2.90
CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell (2006) 2.89
The mammalian Cos2 homolog Kif7 plays an essential role in modulating Hh signal transduction during development. Curr Biol (2009) 2.63
Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1. Nat Immunol (2003) 2.58
Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res (2010) 2.45
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
The ciliary G-protein-coupled receptor Gpr161 negatively regulates the Sonic hedgehog pathway via cAMP signaling. Cell (2013) 2.42
Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood (2002) 1.95
TULP3 bridges the IFT-A complex and membrane phosphoinositides to promote trafficking of G protein-coupled receptors into primary cilia. Genes Dev (2010) 1.95
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol (2005) 1.83
Kinetics of hedgehog-dependent full-length Gli3 accumulation in primary cilia and subsequent degradation. Mol Cell Biol (2010) 1.81
Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci U S A (2005) 1.62
Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood (2002) 1.52
Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum (2007) 1.51
Efficient mitochondrial targeting relies on co-operation of multiple protein signals in plants. J Exp Bot (2008) 1.51
Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood (2004) 1.43
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41
In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis (2003) 1.37
Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood (2007) 1.30
Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. J Biol Chem (2003) 1.29
Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Dev Cell (2011) 1.29
Overexpression of the Notch target genes Hes in vivo induces lymphoid and myeloid alterations. Oncogene (2002) 1.26
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood (2002) 1.22
Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol (2006) 1.20
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood (2009) 1.19
The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res (2003) 1.17
CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol (2008) 1.17
The structure of SHH in complex with HHIP reveals a recognition role for the Shh pseudo active site in signaling. Nat Struct Mol Biol (2009) 1.15
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium. Am J Hematol (2014) 1.15
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood (2013) 1.14
Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active site. J Biol Chem (2010) 1.13
Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer. Prostate (2004) 1.12
Functional characterization of putative cilia genes by high-content analysis. Mol Biol Cell (2011) 1.12
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood (2007) 1.11
Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol (2002) 1.09
Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. Br J Haematol (2012) 1.09
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med (2011) 1.06
In vitro generation of long-lived human plasma cells. J Immunol (2012) 1.04
High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol (2007) 1.03
Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood (2002) 1.03
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood (2007) 1.01
Membrane targeting of palmitoylated Wnt and Hedgehog revealed by chemical probes. FEBS Lett (2011) 1.00
Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol (2014) 0.99
DNA internalized via caveolae requires microtubule-dependent, Rab7-independent transport to the late endocytic pathway for delivery to the nucleus. J Biol Chem (2007) 0.98
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther (2008) 0.98
Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. Cytometry B Clin Cytom (2006) 0.95
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther (2013) 0.94
Polyubiquitination of insulin-like growth factor I receptor (IGF-IR) activation loop promotes antibody-induced receptor internalization and down-regulation. J Biol Chem (2011) 0.93
Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med (2012) 0.92
t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosomes Cancer (2006) 0.92
Metal oxide-coated three-dimensional graphene prepared by the use of metal-organic frameworks as precursors. Angew Chem Int Ed Engl (2013) 0.90
Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates. Pharm Res (2014) 0.90
Abeta42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism. Neurobiol Aging (2003) 0.89
The detection of t(14;18) in archival lymph nodes: development of a fluorescence in situ hybridization (FISH)-based method and evaluation by comparison with polymerase chain reaction. J Mol Diagn (2003) 0.89
An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J (2004) 0.89
Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clin Cancer Res (2011) 0.88
Treatment of autoimmune disease by adoptive cellular gene therapy. Ann N Y Acad Sci (2003) 0.88
Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing. Cytometry B Clin Cytom (2010) 0.88
Preparation of MoS2-MoO3 hybrid nanomaterials for light-emitting diodes. Angew Chem Int Ed Engl (2014) 0.87
B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle. Br J Haematol (2007) 0.86
Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Br J Haematol (2007) 0.86
Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem (2008) 0.86